Biotech | December 05, 2021
SPARC to licence Biomodifying’s IP
SPARC will pay Biomodifying a percentage of payments received for sublicenses of the licensed IP
SPARC will pay Biomodifying a percentage of payments received for sublicenses of the licensed IP
MJ will be paid a one-time lumpsum licence fee of Rs 15 crore
The first hospital in Kharadi launched three years ago has made a significant difference to women and children's health
Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
Preclinical data demonstrate sotrovimab, authorised in multiple countries around the world, retains activity against all tested variants of concern, including key mutations of Omicron
The U.S. FDA advisory committee voted 13-10 in favour of the oral antiviral medicine
Oravax's vaccine technology is highly scalable for manufacturing and is easily transferable for wide scale logistical distribution, as there is no need for freezer storage
Transaction adds to Sanofi pipeline a potential first-in-class vaccine candidate in acne vulgaris, a condition affecting millions of people worldwide
One of the very few facilities in India to have this capability, marking a remarkable feat in LifeCell’s expedition to take genome sequencing to the next level in India
TIB Molbiol excels in ultra-rapid assay development for emerging infectious diseases, strongly demonstrated during the Covid-19 pandemic
Subscribe To Our Newsletter & Stay Updated
